Lexicon Pharmaceuticals Inc. has announced new clinical data from a study evaluating sotagliflozin in patients with heart failure with preserved ejection fraction (HFpEF) without diabetes. The results were presented at the American Heart Association (AHA) Annual Scientific Sessions 2025. The randomized, double-blind, placebo-controlled trial, conducted under the direction of Dr. Juan J Badimon at Mount Sinai Medical Center, enrolled 88 racially diverse participants, 70 percent of whom were female. Over a six-month treatment period, patients receiving sotagliflozin demonstrated statistically significant improvements in left ventricular mass, diastolic function, six-minute walk test performance, and Kansas City Cardiomyopathy Questionnaire (KCCQ) scores compared to placebo. While peak VO2 improvement was not statistically significant, a notable trend was observed. This study is reported as the first to demonstrate clinical benefits of sotagliflozin for HFpEF patients without diabetes.